Multigene assays to improve assessment of recurrence risk and benefit from chemotherapy in early-stage colon cancer: Has the time finally arrived, or are we still stage locked?

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages 3904-3907

  Tabernero, Josep ^a   Baselga, José ^a,b  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BIOLOGICAL MARKER; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; LEVAMISOLE; OXALIPLATIN; PROTEIN P53;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; COHORT ANALYSIS; COLON CANCER; COLON SURGERY; COLORECTAL CANCER; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; MEDICAL SOCIETY; MICROARRAY ANALYSIS; MICROSATELLITE INSTABILITY; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECURRENCE RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; CANCER STAGING; COLON TUMOR; GENETICS; NOTE; PATHOLOGY; RECURRENT DISEASE;

CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM STAGING; PROGNOSIS; RECURRENCE;

EID: 77957605125     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.0806     Document Type: Editorial

References (42)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420-1425, 2004 (Pubitemid 39429665)
3. Locker GY, Hamilton S, Harris J, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327, 2006
4. Benson AB 3rd, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408-3419, 2004 (Pubitemid 41103700)
5. Van Cutsem E, Oliveira J: Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 20:49-50, 2009 (suppl 4)
6. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990 (Pubitemid 20042739)
7. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004 (Pubitemid 38702845)
8. André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
9. Twelves C, Wong A, Nowacki MP, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696-2704, 2005 (Pubitemid 41007824)
10. André T, Sargent D, Tabernero J, et al: Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 13:887-898, 2006 (Pubitemid 43727375)
11. Sobrero A: Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal. Lancet Oncol 7:515-516, 2006
12. Köhne CH: Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal. Lancet Oncol 7:516-517, 2006
13. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Colon cancer, v.3.2010. http://www.nccn.org/professionals/physician- gls/PDF/colon.pdf
14. Vilar E, Gruber SB: Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 7:153-162, 2010
15. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-618, 2005 (Pubitemid 46224239)
16. E5202 study (NCT00217737): Oxaliplatin, leucovorin, and fluorouracil with or without bevacizumab in treating patients who have undergone surgery for stage II colon cancer. http://www.clinicaltrials.gov/ct2/show/NCT00217737?term= E5202&rank=1
17. Jen J, Kim H, Piantadosi S, et al: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331:213-221, 1994 (Pubitemid 24226678)
18. Watanabe T, Wu TT, Catalano PJ, et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196-1206, 2001 (Pubitemid 32319494)
19. Watanabe T, Kobunai T, Yamamoto Y, et al: Prognostic significance of 18q loss of heterzygosity in microsatellite-stable colorectal cancer. J Clin Oncol 28:e119, 2010
20. Roth AD, Tejpar S, Yan P, et al: Correlation of molecular markers in colon cancer with satge-specific prognosis results of the translational study on the PETACC3-EORTC40993-SAKK60-00 trial. 2009 Gastrointestinal Cancers Symposium, San Francisco, CA, January 15-17, 2009 (abstr 288)
21. Popat S, Houlston RS: A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 41:2060-2070, 2005 (Pubitemid 41337947)
22. Ahnen DJ, Feigl P, Quan G, et al: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study. Cancer Res 58:1149-1158, 1998 (Pubitemid 28183202)
23. Elsaleh H, Powell B, Soontrapornchai P, et al: p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 58:52-59, 2000 (Pubitemid 30045310)
24. Westra JL, Schaapveld M, Hollema H, et al: Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 23:5635-5643, 2005
25. Roth AD, Tejpar S, Delorenzi M, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466-474, 2010
26. O'Connell MJ, Lavery I, Yothers G, et al: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 28:3937-3944, 2010
27. Bertucci F, Salas S, Eysteries S, et al: Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23:1377-1391, 2004 (Pubitemid 38406833)
28. Wang Y, Jatkoe T, Zhang Y, et al: Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22:1564-1571, 2004 (Pubitemid 41079793)
29. Barrier A, Boelle PY, Roser F, et al: Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24:4685-4691, 2006 (Pubitemid 46630932)
30. Eschrich S, Yang I, Bloom G, et al: Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23:3526-3535, 2005
31. Arango D, Laiho P, Kokko A, et al: Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology 129:874-884, 2005 (Pubitemid 41242680)
32. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
33. Salazar R, Bender RA, Bruin S, et al: Development and validation of a robust high-throughput gene expression test (ColoPrint) for risk stratification of colon cancer patients. 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 22-24, 2010 (abstr 295)
34. PARSC study (NCT00903565): A prospective study for the assessment of recurrence risk in stage II colon cancer patients using ColoPrint (PARSC) http://www.clinicaltrials.gov/ct2/show/NCT00903565?term=PARSC&rank=1
35. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004 (Pubitemid 40051905)
36. Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721-728, 2008 (Pubitemid 351264384)
37. Paik S, Tang G , Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006 (Pubitemid 46622311)
38. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
39. Cardoso F, Van't Veer L, Rutgers E, et al: Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 26:729-735, 2008 (Pubitemid 351264385)
40. Ma XJ, Hilsenbeck SG, Wang W, et al: The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24:4611-4619, 2006 (Pubitemid 46630959)
41. Wang Z, Dahiya S, Provencher H, et al: The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer. Clin Cancer Res 13:6327-6334, 2007
42. Ma XJ, Salunga R, Dahiya S, et al: A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14:2601-2608, 2008